Back

What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER?

Cardiovascular Research

3 January 2019
Organised by: Logo
Read full article
ESC Journals

Contributors

Maciej Banach
Maciej Banach

Author

Peter E Penson
Peter E Penson

Author

You may be interested in
thumbnail
Webinar
How to treat patients with borderline dyslipidemia
8 February 2023
thumbnail
Congress Presentation
Effect of PCSK9 inhibitors on coronary plaque: a meta-analysis and trial sequential analysis
1 September 2025
thumbnail
Congress Presentation
Cardiovascular Efficacy of Evolocumab in Patients with Obesity: Updates from FOURIER Trial
2 September 2024
thumbnail
Congress Presentation
Carotid plaques stabilization and regression with evolocumab
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources